M. Scott Lucia MDProfessor and Vice Chair of Anatomic Pathology, Chief of Genitourinary Pathology, Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO
Dr. Lucia served as the primary pathologist for the Prostate Cancer Prevention Trial (PCPT) and Vitamin E and Selenium Chemoprevention Trial (SELECT), sponsored by the Southwest Oncology Group, the Medical Therapy of Prostate Symptoms (MTOPS) trial, sponsored by the NIDDK, and the Reduction with Dutasteride of Clinical Progression Events in Expectant Management of Prostate Cancer (REDEEM) sponsored by GlaxoSmithKline. He directs the operation of several tissue and serum biorepositories for prostate and prostatic diseases including those for the PCPT, MTOPS, SELECT, and the University of Colorado Cancer Center Prostate Biorepository. He has authored or co-authored over 160 peer-reviewed articles, reviews, editorials and/or book chapters. His primary areas of interest include pathology of prostate cancer and hyperplasia, early detection and prevention of prostate cancer, prostate cancer biomarkers, and mechanisms of carcinogenesis.
Part owner of the startup company, 3DBiopsy, that produces materials (registration software, biopsy collection kits and needles) to aid physicians in improved targeted focal therapy.